Publications by Dr Jess Dyson - ePrints

Browsing publications by Dr Jess Dyson.

Newcastle Authors	Title	Year
Dr Aaron Wetten Dr Jess Dyson Professor David Jones	Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?	2024
Dr Aaron Wetten Dr Jess Dyson Professor David Jones	Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis	2024
Professor Stuart McPherson Dr Jess Dyson Dr Laura Jopson Dr Steven Masson Professor Quentin Anstee et al.	How effective are experienced hepatologists at staging fibrosis using non-invasive fibrosis tests in patients with metabolic dysfunction-associated steatotic liver disease?	2024
Professor Stuart McPherson Dr Jess Dyson Dr Steven Masson Professor Quentin Anstee	Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply	2024
Professor Stuart McPherson Dr Jess Dyson Dr Laura Jopson Dr Steven Masson Professor Quentin Anstee et al.	Letter: Beyond advanced fibrosis—The critical need for assessing NITs performance in identifying F2-F3 fibrosis. Authors' reply	2024
Dr Jess Leighton Professor David Jones Dr Jess Dyson Professor Heather Cordell	Network proximity analysis as a theoretical model for identifying potential novel therapies in primary sclerosing cholangitis	2024
Dr Jess Dyson	Prognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantation	2024
Lucy Gee Dr Ben Barron-Millar Dr Marco Zaki Dr Saimir Luli Rachel Burgoyne et al.	Anti–Cholestatic Therapy with Obeticholic Acid Improves Short-Term Memory in Bile Duct–Ligated Mice	2023
Dr Jess Dyson Professor David Jones	Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis	2023
Dr Jess Leighton Dr Lin Lee Wong Dr Anna Goulding Dr Penney Gray Professor David Jones et al.	Patient Priorities in Autoimmune Hepatitis: The Need for Better Treatments, More Education and Challenging Stigma	2023
Dr Jess Dyson Dr April Phaw Dr Vinod Hegade Dr George Mells Professor David Jones et al.	UK-Wide Multicenter Evaluation of Second-line Therapies in Primary Biliary Cholangitis	2023
Dr Daniel Geh Robyn Watson Gourab Sen Jeremy French John Hammond et al.	COVID-19 and liver cancer: Lost patients and larger tumours	2022
Dr Jess Dyson	Editorial: autoimmune hepatitis and metabolic syndrome-associated disease development—an important question but only part of the answer?	2022
Dr Aaron Wetten Dr Jess Dyson Professor David Jones	Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis	2022
Dr Aaron Wetten Dr Laura Ogle Dr George Mells Dr Vinod Hegade Dr Laura Jopson et al.	Neurosteroid Activation of GABA-A Receptors: A Potential Treatment Target for Symptoms in Primary Biliary Cholangitis?	2022
Dr Jess Dyson Professor David Jones Professor John Sayer	Primary biliary cholangitis presenting with Fanconi syndrome: An important phenotype	2022
Dr David Adams Dr Jess Dyson	Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis	2022
Abdullah Malik Professor Sanjay Pandanaboyana Gourab Sen Professor Stuart McPherson Dr Jess Dyson et al.	Risk factors for decompensation and death following umbilical hernia repair in patients with end-stage liver disease	2022
Dr Aaron Wetten Professor David Jones Dr Jess Dyson	Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC)	2022
Dr Jess Dyson Professor David Jones	Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group	2022
Professor David Jones Dr Aaron Wetten Dr Ben Barron-Millar Dr Laura Ogle Dr George Mells et al.	The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study	2022
Dr Jess Dyson Professor David Jones	Bezafibrate for the Treatment of Cholestatic Pruritus: Time for a Change in Management?	2021
Dr Jess Dyson Dr Alasdair Blain Dr Mark Hudson Professor Stephen Rushton Professor David Jones et al.	Geo-epidemiology and environmental co-variate mapping of primary biliary cholangitis and primary sclerosing cholangitis	2021
Dr Laura Neilson Dr Louise MacDougall Dr Timothy Hardy Dr David Beaton Dr April Phaw et al.	Implementation of a care bundle improves the management of patients with non-alcoholic fatty liver disease	2021
Dr April Phaw Dr Jess Leighton Dr Jess Dyson Professor David Jones	Managing cognitive symptoms and fatigue in cholestatic liver disease	2021
Dr Jess Leighton Dr Jess Dyson Professor David Jones	Patient ownership of primary biliary cholangitis long-Term management	2021
Dr Aaron Wetten Professor David Jones Dr Jess Dyson	Specific considerations for the management of primary biliary cholangitis: are the drug treatment options good enough?	2021
Dr Ben Barron-Millar Dr Laura Ogle Emeritus Professor John Kirby Dr Jeremy Palmer Dr Laura Jopson et al.	The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis	2021
Dr April Phaw Dr Jess Dyson Professor David Jones	Understanding Fatigue in Primary Biliary Cholangitis	2021
Dr April Phaw Dr Jess Dyson Professor David Jones	Emerging drugs for the treatment of primary biliary cholangitis	2020
Dr Jess Dyson Steven White	Pregnancy outcomes in women with liver transplants: systematic review and meta-analysis	2020
Dr Jess Dyson	Review article: experimental therapies in autoimmune hepatitis	2020
Dr Jess Dyson Professor David Jones	UDCA prophylaxis for post-transplant PBC recurrence prevention: Time to change practice	2020
Dr Jess Dyson Professor David Jones	British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis	2019
Dr Jess Dyson Dr Mark Hudson	Paediatric to adult liver transition services: the state of play in the UK	2019
Dr Jess Dyson Dr Mark Hudson	Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: Fourth report of the Lancet Standing Commission on Liver Disease in the UK	2018
Dr Jess Dyson Dr Lin Lee Wong Dr Theophile Bigirumurame Dr Stuart Kendrick Professor David Jones et al.	Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom	2018
Dr Jess Dyson Professor David Jones Dr Mark Hudson	Primary sclerosing cholangitis	2018
Dr Jess Dyson Dr Dina Tiniakos Professor David Jones	The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines	2018
Dr Lin Lee Wong Dr Holly Fisher Dr Deborah Stocken Stephen Rice Dr Amardeep Khanna et al.	The Impact of Autoimmune Hepatitis and Its Treatment on Health Utility	2018
Dr Jess Dyson	Adult parenteral nutrition in the North of England: A region-wide audit	2017
Professor Stuart McPherson Dr Jess Dyson Dr Mark Hudson	Editorial: improving in-hospital management of decompensated cirrhosis by a ‘care bundle’ – hope, frustration and lessons to learn. Authors’ reply	2017
Dr Jess Dyson Dr Mark Hudson	New metrics for the Lancet Standing Commission on Liver Disease in the UK	2017
Dr Gary Reynolds Dr Lin Lee Wong Professor David Jones Dr Jess Dyson	Balance between exhausted regulatory T cells and CD161(+) NK cells is crucial in acute AIH pathogenesis	2016
Kile Green Dr Laura Jopson Dr Ben Barron-Millar Barbara Innes Sarah Pagan et al.	Early Molecular Stratification of High-risk Primary Biliary Cholangitis	2016
Dr Jess Dyson Professor David Jones	Early Primary Biliary Cholangitis is Characterised by Brain Abnormalities on Cerebral Magnetic Resonance Imaging	2016
Dr Jess Dyson Professor Chris Lamb Dr Steven Masson Dr Mark Hudson Dr Christian Dipper et al.	Implementation of a “care bundle” improves the management of patients admitted to hospital with decompensated cirrhosis	2016
Dr Jess Dyson Dr Laura Jopson Dr Sheila Waugh Professor Stuart McPherson	Improving testing for hepatitis B before treatment with rituximab	2016
Dr Jess Dyson Dr Dina Tiniakos Professor Stuart McPherson	Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use	2016
Dr Vinod Hegade Dr Amardeep Khanna Dr Lucy Walker Dr Lin Lee Wong Dr Jess Dyson et al.	Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score	2016
Dr Jess Dyson Professor Stuart McPherson	Reply to "Liver Failure in Human Immunodeficiency Virus - Hepatitis C Virus Coinfection Treated with Sofosbuvir, Ledipasvir and Antiretroviral Therapy"	2016
Professor Stuart McPherson Dr Jess Dyson Dr Mark Hudson	Response to the NCEPOD report: development of a care bundle for patients admitted with decompensated cirrhosis—the first 24 h	2016
Dr Jess Dyson Dr Nina Wilson Dr Laura Jopson Samantha Ducker Dr Deborah Stocken et al.	The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis	2016
Dr Lin Lee Wong Dr Stuart Kendrick Professor David Jones Dr Jess Dyson	UK-AIH - Highlighting the need for standardization of treatment in autoimmune hepatitis	2016
Dr Laura Jopson Dr Jess Dyson Professor David Jones	Understanding and Treating Fatigue in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis	2016
Dr Jess Dyson Dr Jeremy Palmer Dr Lin Lee Wong Dr Stuart Kendrick Professor David Jones et al.	Understanding the importance of pro- and anti-inflammatory cytokines in autoimmune hepatitis	2016
Dr Lin Lee Wong Dr Stuart Kendrick Dr Jess Dyson Professor David Jones	Understanding the unmet need in Autoimmune Hepatitis - The United Kingdom AIH Study (UK-AIH)	2016
Dr Jess Dyson Dr Steven Masson Professor Stuart McPherson Professor Derek Manas Dr Mark Hudson et al.	Experience of Using Advagraf in a Single Liver Transplant Centre in the United Kingdom	2015
Dr Jess Dyson Dr Ahmed Elsharkawy Professor Chris Lamb Dr Ahmad Al-Rifai Emerita Professor Julia Newton et al.	Fatigue in primary sclerosing cholangitis is associated with sympathetic over-activity and increased cardiac output	2015
Kile Green Sarah Pagan Dr Jess Dyson Dr Lucy Walker Dr Laura Jopson et al.	High-risk primary biliary cirrhosis has a distinct molecular signature opening the way for a molecular approach to stratified therapeutics	2015
Dr Jess Dyson Dr Steven Masson Professor Stuart McPherson Dr Mark Hudson	Impact of a Nurse-Led Annual Review Clinic for Liver Transplant Recipients	2015
Dr Jess Dyson Professor Chris Lamb Dr Mark Hudson Professor Stuart McPherson	Implementation and impact of a care bundle for the management of patients with decompensated liver disease	2015
Dr Jess Dyson Dr Mark Hudson	Implementation of the Lancet Standing Commission on Liver Disease in the UK	2015
Dr Jess Dyson Professor Stuart McPherson Dr Steven Masson Dr Mark Hudson	Importance of Health Education in an Annual Review Liver Transplant Clinic in the United Kingdom	2015
Dr Jess Dyson Professor Quentin Anstee Professor Stuart McPherson	Non-alcoholic fatty liver disease: a practical approach to treatment	2015
Dr Jess Dyson Professor Derek Mann Professor David Jones	Novel therapeutic targets in primary biliary cirrhosis	2015
Dr Jess Dyson Dr Laura Jopson Professor Stuart McPherson	Rituximab and hepatitis B: are we doing it right?	2015
Dr Jess Dyson Professor David Jones	Unmet clinical need in autoimmune liver diseases	2015
Dr Jess Dyson Dr Mark Hudson Professor Derek Manas Dr Steven Masson	A Positive Complement Dependent Cytotoxic (CDC) Crossmatch Does Not Impact on Patient Survival or Increase the Risk of Acute Cellular Rejection, or Biliary Strictures after Liver Transplantation	2014
Dr Jess Dyson Dr Laura Jopson Samantha Ducker Professor David Jones	Age at Presentation and Gender are Predictors of Increased Mortality Over Long-Term Follow-Up in Primary Biliary Cirrhosis (PBC)	2014
Dr Jess Dyson Professor David Jones	Diagnosis and Management of Patients with primary biliary cirrchosis	2014
Dr Jess Dyson Dr Dipanker Chattopadhyay Rajiv Lochan Jayadeva Dr Imran Patanwala Mike Cole et al.	Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team	2014
Dr Jess Dyson Dr Mark Hudson Professor Stuart McPherson	Lesson of the month 2: Severe reactivation of hepatitis B after immunosuppressive chemotherapy	2014
Dr Jess Dyson Professor Stuart McPherson Professor Quentin Anstee	Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification	2014
Dr Jess Dyson Professor James Mason Dr Matthew Rutter	Prior hysterectomy and discomfort during colonoscopy: a retrospective cohort analysis	2014
Dr Jess Dyson Dr Laura Jopson Samantha Ducker Professor David Jones	The Impact of Age at Presentation on Symptoms in Primary Biliary Cirrhosis	2014
Dr Laura Jopson Dr Jess Dyson Professor David Jones	The New Epidemiology of Primary Biliary Cirrhosis	2014
Dr Jess Dyson Professor Chris Day	Treatment of Non-Alcoholic Fatty Liver Disease	2014
Dr Jeremy Palmer Professor David Jones Dr Jess Dyson Emeritus Professor John Kirby	Understanding the Mechanisms Underpinning Treatment Non-Response in Primary Biliary Cirrhosis: A Tool for Treatment Stratification	2014
Dr Jeremy Palmer Dr Jess Dyson Professor David Jones Emeritus Professor John Kirby	Understanding the mechanisms underpinning treatment non-response in Primary Biliary Cirrhosis: a tool for treatment stratification	2014
Dr Laura Jopson Professor David Jones Dr Jess Dyson	Younger patients presenting with Primary Biliary Cirrhosis are more likely to have cognitive impairment	2014
Dr Jess Dyson Professor Stuart McPherson Professor Quentin Anstee	Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification	2013